Skip to main content

Ault Milton C III's Form 4 filing

Alzamend Neuro, Inc. (ALZN) · filed Aug 4, 2026

Accession no.
0001214659-26-009594
Filed
Aug 4, 2026, 9:35 PM ET
Trade date
Jul 31, 2026
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 1 derivative transaction. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Ault Milton C IIICIK 0001212502Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

This filing has no transactions of this kind.

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jul 31, 2026Series D Convertible Preferred StockAGrant or awardAcquired+7,500$1,000.00+$7,500,0007,500Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Remarks

Mr. Ault, the Executive Chairman of HSD, which wholly owns ACG, which in turn wholly owns Ault Lending, is a director of the Issuer. For purposes of Section 16 of the Exchange Act, each of HSD, ACG and Ault Lending may be deemed a director by deputization by virtue of their respective representation on the Board of Directors of the Issuer.

Read the full filing on SEC EDGAR (opens in a new tab)